Cargando…
Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens
Autores principales: | Maiti, Abhishek, Rausch, Caitlin R., Cortes, Jorge E., Pemmaraju, Naveen, Daver, Naval G., Ravandi, Farhad, Garcia-Manero, Guillermo, Borthakur, Gautam, Naqvi, Kiran, Ohanian, Maro, Short, Nicholas J., Alvarado, Yesid, Kadia, Tapan M., Takahashi, Koichi, Yilmaz, Musa, Jain, Nitin, Kornblau, Steven, Montalban-Bravo, Guillermo, Sasaki, Koji, Andreeff, Michael, Bose, Prithviraj, Ferrajoli, Alessandra, Issa, Ghayas C., Jabbour, Elias J., Masarova, Lucia, Thompson, Philip A., Wang, Sa, Konoplev, Sergej, Pierce, Sherry A., Ning, Jing, Qiao, Wei, Welch, John S., Kantarjian, Hagop M., DiNardo, Courtney D., Konopleva, Marina Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927994/ https://www.ncbi.nlm.nih.gov/pubmed/32499238 http://dx.doi.org/10.3324/haematol.2020.252569 |
Ejemplares similares
-
Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents
por: Hammond, Danielle, et al.
Publicado: (2023) -
P736: ANALYSIS OF RESPONSE RATES AND OUTCOMES IN ERYTHROID-PREDOMINANT MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH VENETOCLAX-BASED REGIMENS
por: Bazinet, Alexandre, et al.
Publicado: (2023) -
Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
por: Maiti, Abhishek, et al.
Publicado: (2021) -
Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML
por: Yilmaz, Musa, et al.
Publicado: (2022) -
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
por: Short, Nicholas J., et al.
Publicado: (2023)